Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joanne E Mortimer

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Oncology (Williston Park, N.Y.)|April 17, 2010
Lessons learned from the use of ESAsJoanne E Mortimer
Current Opinion in Obstetrics & Gynecology|December 19, 2009
Managing the toxicities of the aromatase inhibitorsJoanne E Mortimer
Geriatrics|September 26, 2002
Hormone replacement therapy and beyond. The clinical challenge of menopausal symptoms in breast cancer survivorsJoanne E Mortimer
JAMA Oncology|May 24, 2022
Who Will Benefit From Metformin?Joanne E Mortimer, Victoria Seewaldt
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 11, 2025
The Role of HER2 PET in Treatment of Breast CancerJames R Bading, Joanne E Mortimer
Breast Cancer Research : BCR|October 29, 2003
Positron emitting 18F-2-deoxy-2-fluoro-D-glucose: potential hot new therapyJoanne E Mortimer, Marie E Taylor
Oncology (Williston Park, N.Y.)|June 13, 2003
Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agentsJoanne E Mortimer, Janice H Urban
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 22, 2018
Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers and a Note about NOTAJoanne E Mortimer, John E Shively
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2024
The Role of Molecular Imaging in Precision OncologyJames R Bading, Joanne E Mortimer
Seminars in Oncology|August 5, 2010
Safety considerations for use of bone-targeted agents in patients with cancerJoanne E Mortimer, Sumanta Kumar Pal
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Oncology (Williston Park, N.Y.)|April 17, 2010
Lessons learned from the use of ESAsJoanne E Mortimer
Current Opinion in Obstetrics & Gynecology|December 19, 2009
Managing the toxicities of the aromatase inhibitorsJoanne E Mortimer
Geriatrics|September 26, 2002
Hormone replacement therapy and beyond. The clinical challenge of menopausal symptoms in breast cancer survivorsJoanne E Mortimer
JAMA Oncology|May 24, 2022
Who Will Benefit From Metformin?Joanne E Mortimer, Victoria Seewaldt
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 11, 2025
The Role of HER2 PET in Treatment of Breast CancerJames R Bading, Joanne E Mortimer
Breast Cancer Research : BCR|October 29, 2003
Positron emitting 18F-2-deoxy-2-fluoro-D-glucose: potential hot new therapyJoanne E Mortimer, Marie E Taylor
Oncology (Williston Park, N.Y.)|June 13, 2003
Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agentsJoanne E Mortimer, Janice H Urban
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 22, 2018
Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers and a Note about NOTAJoanne E Mortimer, John E Shively
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 3, 2024
The Role of Molecular Imaging in Precision OncologyJames R Bading, Joanne E Mortimer
Seminars in Oncology|August 5, 2010
Safety considerations for use of bone-targeted agents in patients with cancerJoanne E Mortimer, Sumanta Kumar Pal
Pageof 7